www.aobiome.com
Open in
urlscan Pro
173.236.236.149
Public Scan
Submitted URL: http://aobpharma.com/
Effective URL: https://www.aobiome.com/
Submission: On November 25 via api from US — Scanned from US
Effective URL: https://www.aobiome.com/
Submission: On November 25 via api from US — Scanned from US
Form analysis
0 forms found in the DOMText Content
Skip to content AOBiome * Our Science * AOB and it’s impact on Inflammatory Conditions, and related Systemic Effects * Published Articles and Papers * Pipeline * Press * Company News * Press Releases * Conferences and Events * About Us * Leadership * Board * Investors * Contact Us LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS Learn More • LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS Learn More AN EVOLUTIONARY APPROACH TO RESTORING HEALTH AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of class defining Ammonia Oxidizing Bacteria (AOB), whose presence on the skin has been eliminated through modern living. RESTORING IMMUNE FUNCTIONALITY Ammonia Oxidizing Bacteria may serve to restore proper immune response through the down regulation of IL-4, IL-5, IL-13 and IL-31. Such markers are associated with inappropriate inflammatory response in several diseases including the pruritus (itch) pathway. AOBIOME CURRENTLY HAS MULTIPLE PHASE 2 CLINICAL PROGRAMS AOBIOME CURRENTLY HAS PHASE 2 CLINICAL PROGRAMS IN ACNE, ECZEMA AND ROSACEA. Learn More COMMITTED TO TRANSFORMING & IMPROVING HUMAN HEALTH We believe that the restoration of the symbiotic relationship between bacteria and humans will have a profound impact on human health. Clinical Trials Science Manufacturing Pipeline Clinical Trials Science Manufacturing About In the News May 16, 2023 · Cambridge, MA AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus Read More April 6, 2023 · Cambridge, MA AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244 Read More November 22, 2022 · Cambridge, MA Todd Krueger, the President & CEO of AOBiome Therapeutics, Inc., featured in Business Talk’s latest edition, “Top 10 Global Business Leaders Making a Difference in 2022” Read More September 27, 2022 · Cambridge, MA AOBiome Listed by The Silicon Review as one of the 50 Innovative companies to watch in 2022 Read More Read More * Our Science * AOB and it’s impact on Inflammatory Conditions, and related Systemic Effects * Published Articles and Papers * Pipeline * Press * Company News * Press Releases * Conferences and Events * About Us * Leadership * Board * Investors * Contact Us © 2019 AOBiome | Terms & Conditions | Site Credits